The scope and potentials of functional radionuclide imaging towards advancing personalized medicine in oncology: Emphasis on PET-CT

Discovery Medicine

Volumn 13, Issue 68, 2013, Pages 65-73

  Basu, Sandip ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; METHODOLOGY; NEOPLASM; PERSONALIZED MEDICINE; REVIEW; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84862299425     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Alavi JB, Alavi A, Chawluk J, Kushner M, Powe J, Hickey W, Reivich M. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 62(6):1074-1078, 1988.
2. Almeida FA, Uzbeck M, Ost D. Initial evaluation of the nonsmall cell lung cancer patient: diagnosis and staging. Curr Opin Pulm Med 16(4):307-314, 2010.
3. Basu S, Mahne A, Iruvuri S, Alavi A. Potential clinical role of fluorodeoxyglucose-positron emission tomography in assessing primary or secondary lymphomas of the parotid gland. Clin Lymphoma Myeloma 7(4):309-314, 2007a.
4. Basu S, Nair N, Mohandas KM. FDG-avid thyroid incidentaloma in advanced gastrointestinal stromal tumor: metachronous dual primaries. Indian J Gastroenterol 26(3):146-147, 2007b.
5. Basu S, Alavi A. Staging with PET and the "Will Rogers" effect: redefining prognosis and survival in patients with cancer. Eur J Nucl Med Mol Imaging 35(1):1-4, 2008a.
6. Basu S, Mavi A, Cermik T, Houseni M, Alavi A. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology?. Mol Imaging Biol 10(1):62-66, 2008b.
7. Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 112(5):995-1000, 2008c.
8. Basu S, Mohandas KM, Peshwe H, Asopa R, Vyawahare M. FDG-PET and PET/CT in the clinical management of gastrointestinal stromal tumor. Nucl Med Commun 29(12):1026-1039, 2008d.
9. Basu S, Zhuang H, Torigian DA, Rosenbaum J, Chen W, Alavi A. Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med 39(2):14-145, 2009a.
10. Basu S, Zhuang H, Torigian DA, Rosenbaum J, Chen W, Alavi A, . Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med 39( 2): 124-145, 2009a
11. Basu S, Asopa RV, Baghel NS Early documentation of therapeutic response at 6 weeks following corticosteroid therapy in extensive sarcoidosis: promise of FDG-PET. Clin Nucl Med 34(10):689-690, 2009b.
12. Basu S. Early FDG-PET response-adapted risk stratification and further therapeutic decision-making in lymphoma: will this replace the established prognostic indices and be the standard-of-care in clinical management?. Eur J Nucl Med Mol Imaging 36(12):2089-2090, 2009c.
13. Basu S. From pure research imaging tool to PET-guided personalized medicine in oncology: a true revolution in modern medicine. Indian J Cancer 47(2):98-99, 2010a.
14. Basu S. PET and PET/CT in gastrointestinal stromal tumours: the unanswered questions and the potential newer applications. Eur J Nucl Med Mol Imaging 37(7):1255-1258, 2010b.
15. Basu S. Personalized versus evidence-based medicine with PET-based imaging. Nat Rev Clin Oncol 7(11):665-668, 2010c.
16. Basu S, Kwee TC, Gatenby R, Saboury B, Torigian DA, Alavi A. Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders. Eur J Nucl Med Mol Imaging 38(6):987-991, 2011a.
17. Basu S, Saboury B, Werner T, Alavi A. Clinical utility of FDG-PET and PET/CT in non-malignant thoracic disorders. Mol Imaging Biol 13(6):1051-1060, 2011b.
18. Basu S. 18F-FDG PET/CT as a sensitive and early treatment monitoring tool: Will this become the major thrust for its clinical application in infectious and inflammatory disorders?. J Nucl Med 53(1):165, 2012.
19. Cerci JJ, Pracchia LF, Linardi CC, Pitella FA, Delbeke D, Izaki M, Trindade E, Soares J, Jr, Buccheri V, Meneghetti JC. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med 51(9):1337-1343, 2010.
20. Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 29(14):1844-1854, 2011.
21. Cremerius U, Fabry U, Wildberger JE, Zimny M, Reinartz P, Nowak B, Schaefer W, Buell U, Osieka R. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 30(2):103-111, 2002.
22. Crocchiolo R, Canevari C, Assanelli A, Lunghi F, Tassara M, Stanghellini ML, Clerici D, Landoni C, Servida P, Bernardi M, Peccatori J, Ferreri A, Gianolli L, Bordignon C, Caligaris-Cappio F, Ciceri F, Fazio F. Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Leuk Lymphoma 49(4):727-733, 2008.
23. De Ruysscher D, van Baardwijk A, Steevens J, Botterweck A, Bosmans G, Reymen B, Wanders R, Borger J, Dingemans AM, Bootsma G, Pitz C, Lunde R, Geraedts W, Oellers M, Dekker A, Lambin P. Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: A prospective population-based study. Radiother Oncol, epub ahead of print, Nov. 17, 2011.
24. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, van Dongen GA, Schröder CP, Lub-de Hooge MN, de Vries EG. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87(5):586-592, 2010.
25. Dührsen U, Hüttmann A, Jöckel KH, Müller S. Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas - the PETAL trial. Leuk Lymphoma 50(11):1757-1760, 2009.
26. Edet-Sanson A, Dubray B, Doyeux K, Back A, Hapdey S, Modzelewski R, Bohn P, Gardin I, Vera P. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC). Radiother Oncol, epub ahead of print, Aug. 30, 2011.
27. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 349 (23):2241-2252, 2003.
28. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon: stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312 (25):1604-1608, 1985.
29. Fleckenstein J, Hellwig D, Kremp S, Grgic A, Gröschel A, Kirsch CM, Nestle U, Rübe C. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial. Int J Radiat Oncol Biol Phys 81(4):e283-e289, 2011.
30. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25(24):3746-3752, 2007.
31. Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small cell lung cancer - a meta-analysis. Ann Intern Med 139(11):879-892, 2003.
32. Gupta K, Pawaskar A, Basu S, Rajan MG, Asopa RV, Arora B, Nair N, Banavali S. Potential role of FDG PET imaging in predicting metastatic potential and assessment of therapeutic response to neoadjuvant chemotherapy in Ewing sarcoma family of tumors. Clin Nucl Med 36(11):973-977, 2011.
33. Haug AR, Auernhammer CJ, Wängler B, Schmidt GP, Uebleis C, Göke B, Cumming P, Bartenstein P, Tiling R, Hacker M. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 51(9):1349-1356, 2010.
34. Huang W, Zhou T, Ma L, Sun H, Gong H, Wang J, Yu J, Li B. Standard uptake value and metabolic tumor volume of 1F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging 38(9):1628-1635, 2011.
35. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med 50(Suppl 1):21S-30S, 2009.
36. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 85(6):613-618, 2000.
37. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25(5):571-578, 2007.
38. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43(8):1018-1027, 2002.
39. Kozak MM, Murphy JD, Schipper ML, Donington JS, Zhou L, Whyte RI, Shrager JB, Hoang CD, Bazan J, Maxim PG, Graves EE, Diehn M, Hara WY, Quon A, Le QT, Wakelee HA, Loo BW, Jr. Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer. J Thorac Oncol 6(5):920-926, 2011.
40. Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM, Ellis GK, Lawton TJ, Livingston RB, Petra PH, Link JM, Krohn KA, Mankoff DA. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res 17(14):4799-4805, 2011.
41. Mavi A, Lakhani P, Zhuang H, Gupta NC, Alavi A. Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer. Radiol Clin North Am 43(1):1-21, 2005.
42. Meng X, Loo BW, Jr, Ma L, Murphy JD, Sun X, Yu J. Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study. J Nucl Med 52(10):1573-1579, 2011.
43. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma: comparison with CT. Leuk Lymphoma 39(5-6):543-553, 2000.
44. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16(9):1514-1523, 2005.
45. Mishani E, Abourbeh G, Eiblmaier M, Anderson CJ. Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Curr Pharm Des 14(28):2983-2998, 2008.
46. Ramani SK, Basu S, Parmar V, Gujral S, Bibte S. Second primary malignancy of breast in a patient of gastrointestinal stromal tumor presenting as fluoro-deoxyglucose-avid breast incidentaloma in fluoro-deoxyglucose-positron emission tomography. J Cancer Res Ther 7(3):387-389, 2011.
47. Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF, Heelan RT, MacApinlac HA, Jung SH, Silvestri GA, Siegel BA, Rusch VW. Results of the American College of Surgeons Oncology Group Z0050 Trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 126(6):1943-1951, 2003.
48. Schiepers C, Filmont JE, Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 30(Suppl 1):S82-S88, 2003.
49. Schwarz JK, Grigsby PW, Dehdashti F, Delbeke D. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med 50(Suppl 1):64S-73S, 2009.
50. Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Metabolic response on posttherapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys, epub ahead of print, Oct. 17, 2011.
51. Skehan SJ, Brown AL, Thompson M, Young JE, Coates G, Nahmias C. Imaging features of primary and recurrent esophageal cancer at FDG PET. Radiographics 20(3):713-723, 2000.
52. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G. Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 13(9):1356-1363, 2002.
53. Sunaga N, Oriuchi N, Kaira K, Yanagitani N, Tomizawa Y, Hisada T, Ishizuka T, Endo K, Mori M. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer 59(2):203-210, 2008.
54. Schwarz JK, Grigsby PW, Dehdashti F, Delbeke D. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med 50(Suppl 1):64S-73S, 2009.
55. Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, Kobayashi M, Ouchi Y. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 31(1):22-28, 2004.
56. Truong MT, Viswanathan C, Erasmus JJ. Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response. J Thorac Imaging 26(2):132-146, 2011.
57. Ullrich RT, Zander T, Neumaier B, Koker M, Shimamura T, Waerzeggers Y, Borgman CL, Tawadros S, Li H, Sos ML, Backes H, Shapiro GI, Wolf J, Jacobs AH, Thomas RK, Winkeler A. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). PLoS One 3(12):e3908, 2008.
58. Verhagen AF, Bootsma GP, Tjan-Heijnen VC, van der Wilt GJ, Cox AL, Brouwer MH, Corstens FH, Oyen WJ. FDG-PET in staging lung cancer-how does it change the algorithm?. Lung Cancer 44(2):175-181, 2004.
59. Walter M A, Benz MR, Hildebrandt IJ, Laing RE, Hartung V, Damoiseaux RD, Bockisch A, Phelps ME, Czernin J, Weber WA. Metabolic imaging allows early prediction of response to vandetanib. J Nucl Med 52(2):231, 2011.
60. Williams RN, Ubhi SS, Sutton CD, Thomas AL, Entwisle JJ, Bowrey DJ. The early use of PET-CT alters the management of patients with esophageal cancer. J Gastrointest Surg 13(5):868-873, 2009.
61. Winkeler A. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). PLoS One 3(12):e3908, 2008.
62. Yang JJ, Wang SX, Zhong WZ, Xu CR, Yan HH, Wu YL. Is 18F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?. Nucl Med Commun 32(12):1113-1120, 2011.
63. Yoon DH, Baek S, Choi CM, Lee DH, Suh C, Ryu JS, Moon DH, Lee JS, Kim SW. FDG-PET as a potential tool for selecting patients with advanced non-small cell lung cancer who may be spared maintenance therapy after first-line chemotherapy. Clin Cancer Res 17(15):5093-5100, 2011.